Another IND application for a new stem cell drug from Heinz Pharmaceuticals was accepted

On November 2, 2022, Tianjin Angsai Cell Genetic Engineering Co.
, Ltd.
, a subsidiary of Heinz Pharmaceutical, declared another clinical IND of new stem cell drugs to the Drug Evaluation Center of the State Food and Drug Administration was accepted
.
Up to now, 7 new stem cell drug IND applications have been accepted, of which 6 stem cell new drugs have obtained implicit approval for
clinical trials.

Acceptance number: CXSL2200553

Drug Name: Mesenchymal stem cells for injection (umbilical cord)

Type of drug: Therapeutic biological products

Application type: New drug

Registration classification: 1 category

Umbilical cord mesenchymal stem cells belong to perinatal stem cells, which have the characteristics of strong proliferation and differentiation ability, abundant quantity, more vitality, low immunogenicity, reuse of waste tissue, no ethical barriers, easy to standardize preparation, etc.
, with a wide range of clinical applications, can be used in a variety of diseases, anti-aging, beauty and other fields, and are favored
by domestic and foreign stem cell research and development pharmaceutical companies.

This time, another clinical IND of new stem cell drug declared by Tianjin Angsai Cell Genetic Engineering Co.
, Ltd.
was accepted, marking a new stage
in the research and development of Heinz combined cell drugs.
Heinkoy Pharmaceutical has independently developed a variety of dosage forms of cell products, and is in a leading position
in the field of new stem cell drug research and development in China.
Heinz Pharmaceutical will continue to increase its investment in the research and development of new cell drugs, actively promote the development of relevant clinical trials, and help domestic stem cell drugs to be launched as soon as possible to benefit people's health
.